Forgot your password?

Forgot your username?

database > company
Opexa Therapeutics
Biotech Specialty Pharma
2635 Technology Forest Blvd.
The Woodlands, TX 77381 USA
phone:281-775-0600
fax:281-872-8585
Symbol OPXA
Exchange NASDAQ
Founded 2001
Employees 25
www.opexatherapeutics.com
Research Sector Biotech Specialty Pharma
Summary Description
Develops treatments for autoimmune diseases.
Management
Neil Warma, President and Chief Executive Officer; Jaye Thompson, Ph.D.,Senior-Vice President of Clinical Development and Regulatory Affairs; Don Healy Ph.D., Vice-President of Scientific Development and Manufacturing; Donna R. Rill, Senior Vice-President of Operations; John Ginzler, Vice-President of Finance;
Ownership
Financials Mkt Cap :20


* numbers in thousands
 

Keywords
Regenerative medicine, immunotherapy, multiple sclerosis, secondary progressive multiple sclerosis, inflammatory disease, MS



Comment | Printable Version | Modify profile |
Updated: Jun. 17, 2013

Description

Opexa Therapeutics (Nasdaq: OPXA) is a biotechnology company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS...

view more

Products / Services

Opexa has recently rebranded its lead therapy with the new name, Tcelnaâ?¢. The product was previously known as Tovaxin. The rebranding of Tcelna encompasses the advancements made to the manufacturing...

view more


Technology / Differentiation

Tcelna is a personalized therapy that is specifically tailored to each patient's disease profile. Tcelna is manufactured using ImmPathâ?¢, Opexa's proprietary method for the production of a patient-sp...

view more

Market / Customers

The company's product candidates have the potential to offer enhanced efficacy, safety and tolerability to address the significant unmet medical needs in several large patient populations. Tcelna h...

view more


Status

Opexa's lead product, Tcelna(tm) (formerly Tovaxin(r)), is a novel T-cell immunotherapy positioned to enter Phase IIb clinical development for the treatment of patients with Secondary Progressive MS (...

view more



2013-06-19-10403